Literature DB >> 122421

Serum prolactin response to thyrotropin-releasing hormone and metoclopramide in patients with prolactin-secreting tumors before and after transsphenoidal surgery.

A Barbarino, L De Marinis, G Maira, E Menini, C Anile.   

Abstract

Seven female patients with amenorrhea, galactorrhea, and hyperprolactinemia were examined before and after selective transsphenoidal removal of a PRL-secreting microadenoma. Before adenomectomy, metoclopramide (MCP; 10 mg orally) and TRH (200 micrograms iv) did not increase PRL blood levels in any of the seven patients. On the contrary, after oral administration of 10 mg MCP, a positive response was noted in a group of eight lactating women 3 days postpartum. After surgery, serum PRL level returned to normal in all patients. A positive PRL response to MCP and TRH was found in six of the seven patients 1 month after surgery. One patient, who had the lowest PRL level, failed to show a PRL increase after both stimuli. These findings indicate that hypothalamic pituitary function can be restored to normal after transsphenoidal removal of PRL-secreting pituitary tumors.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 122421     DOI: 10.1210/jcem-47-5-1148

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  3 in total

1.  Enlarged adenomectomy for enclosed prolactinomas: a preliminary study of 26 cases.

Authors:  F Grisoli; T Brue; N Graziani; R Costa; J Trouillas; D Begou; P Jaquet
Journal:  Acta Neurochir (Wien)       Date:  1990       Impact factor: 2.216

2.  Direct arterial vascularization of estrogen-induced prolactin-secreting anterior pituitary tumors.

Authors:  K A Elias; R I Weiner
Journal:  Proc Natl Acad Sci U S A       Date:  1984-07       Impact factor: 11.205

3.  The inability of dynamic tests of prolactin and TSH secretion to differentiate between tumorous and non-tumorous hyperprolactinemia.

Authors:  R W Prescott; D G Johnston; P K Taylor; J Haigh; D R Weightman; K Hall; D B Cook
Journal:  J Endocrinol Invest       Date:  1985-02       Impact factor: 4.256

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.